肌生成抑制素在2型糖尿病合并动脉粥样硬化中的研究进展

doi:10.3969/j.issn.1003-9198.2022.02.024

摘要/Abstract

中图分类号:

R 54
R 58

董俐, 罗晓红, 牛小娟. 肌生成抑制素在2型糖尿病合并动脉粥样硬化中的研究进展[J]. 实用老年医学, 2022, 36(2): 202-205.

[1] JOSHUA T B, IRFAN M A, MERRY W M, et al. Effect of myostatin deletion on cardiac and microvascular function[J]. Physiol Rep, 2017, 5(23):13525.
[2] MCPHERRON A C, LAWLER A M, LEE S J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member[J]. Nature, 1997, 387(6628):83-90.
[3] SRIRAM S, SUBRAMANIAN S, SATHIAKUMAR D, et al. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB[J]. Aging Cell, 2011, 10(6):931-948.
[4] CLAUS B, NIELSEN A R, FISCHER C P, et al.Plasma and muscle myostatin in relation to type 2 diabetes[J]. PLoS One, 2012, 7(5):37263.
[5] ESTRELLAS K M, CHUNG L, CHEU L A, et al. Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy[J]. J Biol Chem, 2018, 293(40):15594-15605.
[6] TU P, BHASIN S, HRUZ P W, et al. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in ldlr null mice[J]. Diabetes, 2009, 58(8):1739-1748.
[7] 杨瑾, 周播江. 肌肉生长抑制素基因的研究进展[J]. 遵义医学院学报, 2018, 41(4):513-518.
[8] EVELINE A C, MARGREET R, WOUTER J J, et al. Myostatin inhibits vascular smooth muscle cell proliferation and local 14q32 microrna expression, but not systemic inflammation or restenosis[J]. Int J Mol Sci, 2020, 21(10):3508.
[9] LEE S, LEHAR A, LIU Y, et al. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A[J]. Proc Natl Acad Sci U S A, 2020, 117(49):30907-30917.
[10] DELANAYE P, BATAILLE S, QUINONEZ K, et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis[J]. J Renal Nutr, 2019, 29(6):511-520.
[11] CAMPOREZ J G, PETERSEN M C, ABUDUKADIER A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice[J]. Proc Natl Acad Sci U S A, 2016, 113(8):2212-2217.
[12] CAMPOREZ J, PETERSEN M C, ABUDUKADIER A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice[J]. Proc Natl Acad Sci, 2016, 113(8):2212-2217.
[13] WILKES J J, LLOYD D J, GEKAKIS N. Loss-of-function mutation in myostatin reduces tumor necrosis factor[alpha] production and protects liver against obesity-induced insulin resistance[J]. Diabetes, 2009, 58(5):1133-1143.
[14] LAWRENCE T B, ISAAC G, SIMON M, et al. Myostatin is elevated in congenital heart disease and after mechanical unloading[J]. PLoS One, 2011,6(9):23818.
[15] LEBRASSEUR N K. Building muscle, browning fat and preventing obesity by inhibiting myostatin[J]. Diabetologia, 2012, 55(1):13-17.
[16] LIU X, PAN J P, BAUMAN W A, et al. AdipoRon prevents myostatin-induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line[J]. Physiol Rep, 2019, 7(13):14152.
[17] ANTONY N, BASS J J, MCMAHON C D, et al. Myostatin regulates glucose uptake in BeWo cells[J]. Physiol Endocrinol Metab, 2007, 293(5):1296-1302.
[18] SIMONE C, NICHOLE N, ANDREI M C, et al. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue[J]. Physiol Rep, 2020, 8(19):14607.
[19] LU H, ELENA B,YU Z, et al. Combined hyperglycemia-and hyperinsulinemia-induced insulin resistance in adipocytes is associated with dual signaling defects mediated by PKC-ζ[J]. Endocrinology, 2018, 159(4):1658-1677.
[20] IGOR O S, JIANG H F, LIU J, et al. Hepatic stellate cell activation: A source for bioactive lipids[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(5):629-642.
[21] ALEXANDRE M, LUC R, MAUD M, et al. Growth differentiation factor-8(GDF8)/myostatin is a predictor of troponin I peak and a marker of clinical severity after acute myocardial infarction[J]. J Clin Med, 2019, 9(1):116.
[22] 陈羽斐, 沈伟, 施海明. 巨噬细胞免疫代谢与动脉粥样硬化的研究进展[J]. 中国动脉硬化杂志, 2020, 28(1):74-80.
[23] 苑莉莉, 罗彬, 王佳贺. 脂蛋白相关磷脂酶A2在老年糖尿病诊治中的研究进展[J].实用老年医学, 2020, 34(10):1011-1014.
[24] BUTCHER J T, MINTZ J D, LARION S, et al. Increased muscle mass protects against hypertension and renal injury in obesity[J]. J Am Heart Assoc, 2018, 7(16):9358.
[25] BARBARA L B, TIMOTHY S W, PATRICIA G C, et al. Postnatal PPARδ activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice[J]. PLoS One, 2010, 5(6):11307.
[26] MANUEL F L, CARLOTA T, VÍCTOR V, et al. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk[J]. Nutrients, 2019, 11(11):2664.
[27] BOGDANOVICH S, KRAG T O, BARTON E R, et al. Functional improvement of dystrophic muscle by myostatin blockade[J]. Nature, 2002, 420(6914):418-421.
[28] 林金榕, 田家齐, 孙亚英, 等. 肌生成抑制素(MSTN)抗体对肩袖撕裂后肌肉退变的治疗效果[J]. 中国运动医学杂志, 2020, 39(11):870-877.
[29] GREEN D J, HOPMAN M, PADILLA J, et al. Vascular adaptation to exercise in humans: role of hemodynamic stimuli[J]. Physiol Rev, 2017, 97(2):495-528.
[30] WAGNER K R, FLECKENSTEIN J L, AMATO A A, et al. Phase I/II trial of MYO-029 in adult subjects with muscular dystrophy[J]. Ann Neurol, 2008, 63(5):561-571.

肌生成抑制素在2型糖尿病合并动脉粥样硬化中的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	李晓燕, 郁志明. 老年心房颤动合并焦虑状态的研究进展[J]. 实用老年医学, 2024, 38(10): 979-982.
[2]	顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029.
[3]	刘瑾, 黄艳秋, 朱毅, 卓莉莉. 沙库巴曲缬沙坦钠对老年慢性心力衰竭病人的影响[J]. 实用老年医学, 2024, 38(10): 1030-1033.
[4]	徐寿勇, 袁勇. 老年病人开展双低剂量CT冠状动脉造影的可行性研究[J]. 实用老年医学, 2024, 38(10): 1054-1058.
[5]	刘琳, 邬青, 张静, 毛芳莹, 余璐, 任艺婷, 方婷. 老年心力衰竭病人症状感知现状及影响因素分析[J]. 实用老年医学, 2024, 38(5): 461-437.
[6]	王超, 陈晓君. 热带气候对东北地区老年原发性高血压病人血压、外周血microRNA-146a及Hcy的影响[J]. 实用老年医学, 2024, 38(5): 470-437.
[7]	刘倩慧, 姚子俊, 何玉立, 徐云凡, 吴军. 老年2型糖尿病合并慢性心力衰竭病人HbA1c水平对心脏结构和功能的影响[J]. 实用老年医学, 2024, 38(5): 491-437.
[8]	张丽莉, 李静, 丁林锋, 孙静娴, 蔡静波. 颈动脉粥样硬化斑块对非瓣膜性心房颤动病人缺血性脑卒中事件的预测价值[J]. 实用老年医学, 2024, 38(3): 236-239.
[9]	查志敏, 刘欢, 王向明, 李秋爽, 郭妍. 心脏瓣膜钙化对老年冠心病病人预后的影响[J]. 实用老年医学, 2024, 38(3): 245-250.
[10]	陈映泉, 钟勇. 心血管老化的机制、标志物和治疗[J]. 实用老年医学, 2024, 38(3): 299-303.
[11]	朱晨晨, 秦海东. 斑块侵蚀在急慢性冠脉综合征发生发展中的作用[J]. 实用老年医学, 2024, 38(3): 308-311.
[12]	程清, 徐艳, 陈国飞, 邓心悦. 血清血管紧张素Ⅱ和一氧化氮水平与老年慢性心力衰竭病人认知功能障碍的相关性[J]. 实用老年医学, 2024, 38(2): 132-135.
[13]	章颖, 谢玲, 叶佳琦, 羌文慧, 严晓云, 姜英, 张清. 层粘连蛋白与老年急性心肌梗死病人主要不良心血管事件的相关性[J]. 实用老年医学, 2024, 38(2): 149-151.
[14]	段力丹, 习玲, 许建萍. 射血分数正常的老年高血压病人TyG指数与左心室舒张功能的相关性分析[J]. 实用老年医学, 2024, 38(2): 152-156.
[15]	范婷泳, 袁丽, 杨小玲, 陈茜. Caprini量表评估老年糖尿病病人静脉血栓栓塞症的效果[J]. 实用老年医学, 2023, 37(12): 1233-1237.